Is BIO.DE stock a buy on this intraday bounce?

BIO.DE stock can be a tactical buy for short-term traders who use tight stops. Risk control is critical because fundamentals show negative EPS **-0.63** and leverage **1.31**. This is not a long-term recommendation.

What price target should traders watch for BIO.DE stock?

Watch **€43.50** as the first resistance and **€44.50** as a stretch target. Meyka AI's one-year forecast is **€42.05**, so treat intraday targets as short-term, execution-focused levels.

How does Biotest’s valuation affect the trading setup for BIO.DE stock?

Valuation metrics are mixed: price to sales **2.92** and price to book **3.22**. Negative PE reflects losses. These fundamentals increase downside risk beyond intraday trades, so limit exposure accordingly.

Where can I find more real-time data on BIO.DE stock?

Use XETRA feeds, sector reports on MarketBeat, peer comparisons on Investing.com, and the BIO.DE stock page on Meyka AI for live indicators and alerts.

DE Stocks

BIO.DE Biotest AG XETRA 15 Jan 2026: Oversold bounce from €42.20, watch €43.50

ByDanny Kontos January 15, 2026January 15, 2026

BIO.DE stock is staging an intraday oversold bounce after sliding to €42.20 on XETRA. The share is down -0.94% today with volume 175.00 versus an average of 129.00. Traders should watch the immediate resistance at the intraday high €43.00 and the short-term pivot near the 50-day average €42.54. This intraday move offers a defined risk-reward entry for a quick mean-reversion trade while fundamentals and sector context remain mixed.